Kinetic Behaviour of the TFPI and Anti-FXa Effects, after the Injection of a LMWH (RO-11) in Healthy Subjects

• References

• 1 Broze Jr GJ, Warren LA, Novotny WF, Higuchi DA, Girard JJ, Miletich JP. The lipoprotein-associated coagulation inhibitor that inhibits the factor VII- tissue factor complex also inhibits factor Xa: Insight into its possible mechanism of action. Blood 1988; 71: 335-343
• 2 Novotny WF, Girard TJ, Miletich JP, Broze Jr GJ. Purification and characterization of the lipoprotein-associated coagulation inhibitor from human plasma. J Biol Chem 1989; 264: 18832-18837
• 3 Novotny WF, Girard. Miletich JP, Broze Jr GJ. Platelets secrete a coagulation inhibitor functionally and antigenically similar to the lipoprotein-associated coagulation inhibitor. Blood 1988; 72: 2020-2025
• 4 Sandset PM, Abildgaard U, Lie Larsen M. Heparin induces release of extrinsic coagulation pathway inhibitor (EPI). Thromb Res 1988; 50: 803-813
• 5 Bara L, Bloch MF, Zitoun D, Samama MM, Collignon F, Frydman A, Uzan A, Bouthier J. Comparative effects of enoxaparin and unfractionated heparin in healthy volunteers on prothrombin consumption in whole blood during coagulation, and release of tissue factor pathway inhibition. Thromb Res 1993; 69: 443-452
• 6 Wun T-C. Lipoprotein-associated coagulation inhibitor (LACI) is a cofactor for heparin: synergistic anticoagulant action between LACI and sulfated polysaccharides. Blood 1992; 79: 430-438
• 7 Sandset PM, Abildgaard U, Petterssen M. A sensitive assay of extrinsic coagulation pathway inhibitor (EPI) in plasma and plasma fractions. Thromb Res 1987; 47: 489-500
• 8 Yamaoka K, Naragawa T, Uno T. Statistical moments in pharmacokinetics. J Pharmacokin Biopharm 1978; 6: 547-558
• 9 Ariëns RA S, Faioni EM, Mannucci PM. Repeated release of the tissue factor pathway inhibitor. Thromb Haemost 1994; 72: 327-328